Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can an old malaria drug boost Radiation's power against pancreatic cancer?

NCT ID NCT01494155

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding hydroxychloroquine to standard radiation and chemotherapy before surgery can better control pancreatic cancer. About 50 people with resectable pancreatic cancer will receive either proton or photon radiation along with capecitabine and hydroxychloroquine. The study aims to see if this combination improves progression-free survival and increases the chance of a complete response at surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hydroxychloroquine combined with capecitabine and proton or photon radiation therapy
What this could lead to
If successful, this combination could improve control of pancreatic cancer before surgery, potentially extending the time without the disease progressing.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply broadly. The added drug may increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

50 people

The number who actually took part.

Started

Dec 2011

Finished

Sep 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Cytologic or histologic proof of pancreatic ductal carcinoma * Life expectancy \> 3 months * Adequate organ and marrow function Exclusion Criteria: * Evidence of metastatic disease * Pregnant or breast-feeding * Tumors in the body or tail of the pancreas * Serious concomitant systemic disorders such as significant cardiac or pulmonary morbidity (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months, ongoing infection as manifest by fever * Prior chemotherapy or radiation for treatment of the patient's pancreatic tumor * Diagnosis of other invasive carcinomas (except basal cell carcinomas/squamous cell carcinoma of the skin) with the last 5 years. Carcinoma in-situ is allowed. * Other serious uncontrolled medical conditions * Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome * Known, existing uncontrolled coagulopathy * Prior systemic fluoropyrimidine therapy (unless given in an adjuvant setting and completed at least 6 months earlier). Prior unanticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to 5-fluorouracil or known DPD deficiency * Participation in any investigational drug study within 4 weeks preceding the start of study treatment * History of uncontrolled seizures, central nervous system disorders, or psychiatric disability * Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recovery * Currently taking cimetidine * Receiving any other study agents * History of allergic reactions attributed to compounds of similar chemical or biologic composition to capecitabine and HCQ * Already taking HCQ or chloroquine for other diagnosis * History of Grade 3 or greater retinopathy or keratitis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.